Celldex Financial Statements From 2010 to 2025
| CLDX Stock | USD 26.43 0.40 1.54% |
Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
Check out the analysis of Celldex Therapeutics Correlation against competitors. Celldex Therapeutics Company Current Valuation Analysis
Celldex Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Celldex Therapeutics Current Valuation | 1.17 B |
Most of Celldex Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celldex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Celldex Therapeutics has a Current Valuation of 1.17 B. This is 91.83% lower than that of the Biotechnology sector and 74.73% lower than that of the Health Care industry. The current valuation for all United States stocks is 92.94% higher than that of the company.
Celldex Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Celldex Therapeutics's current stock value. Our valuation model uses many indicators to compare Celldex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Celldex Therapeutics competition to find correlations between indicators driving Celldex Therapeutics's intrinsic value. More Info.Celldex Therapeutics is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Celldex Therapeutics' earnings, one of the primary drivers of an investment's value.About Celldex Therapeutics Financial Statements
Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey. Celldex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 132 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.